Evidence map›Paper›PMID 39435480›Full record

ReviewExpert review of gastroenterology & hepatology2024

Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.

Bernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, Claudia A M Fulgenzi, Nichola Awosika, Ciro Celsa, Mario Pirisi, Cristina Rigamonti, Michela Burlone, Federica Vincenzi and 11 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bernardo StefaniniDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Giulia F ManfrediDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Antonio D'AlessioDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Claudia A M FulgenziDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Nichola AwosikaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Ciro CelsaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Mario PirisiDivision of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Cristina RigamontiDivision of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Michela BurloneDivision of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Federica VincenziDivision of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Rosalba MinisiniDivision of Internal Medicine, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Alessandra GennariDivision of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Vincent YipBarts and the London HPB Centre, Royal London Hospital, Whitechapel, UK.
Sarah SlaterBarts and the London HPB Centre, Royal London Hospital, Whitechapel, UK.
Karim El-ShakankeryEdinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK.
Ananya JainDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Francesco TovoliDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Fabio PiscagliaDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Duncan SpaldingHepatobiliary Surgery, Imperial College London and Imperial College NHS Trust, Hammersmith Hospital, London, UK.
Madhava PaiHepatobiliary Surgery, Imperial College London and Imperial College NHS Trust, Hammersmith Hospital, London, UK.
David J PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) presents a formidable challenge in oncology, demanding innovative treatment approaches. Both adjuvant and neoadjuvant therapies, thanks to the introduction of immunotherapy, have emerged as promising strategies in the management of HCC, aiming to reduce the risk of relapse and ultimately to improve survival. AREAS COVERED: This review considers current evidence, ongoing clinical trials, and future strategies to elucidate the evolving landscape of neoadjuvant and adjuvant treatments in HCC. EXPERT OPINION: Both adjuvant and neoadjuvant regimens, notably those incorporating immune checkpoint inhibitors, demonstrated encouraging safety profiles and efficacy outcomes in HCC.While significant challenges persist, including optimizing patient selection and endpoint definition, the evolving landscape of neoadjuvant and adjuvant therapy holds promise for maximizing the therapeutic potential of immunotherapy across all stages of HCC. Further insights into tumor biology and host immunity will shape the role of these approaches which are close to becoming reality in clinical practice.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeoadjuvant TherapyChemotherapy, AdjuvantHumansImmune Checkpoint InhibitorsImmunotherapyNeoplasm Recurrence, LocalNeoplasm StagingImmune Checkpoint Inhibitorsadjuvanthepatocellular carcinomaimmune checkpoint inhibitorsImmunotherapyneoadjuvant

Identifiers

PMID39435480
PMCPMC11601036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.